DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in ZEMDRI is plazomicin sulfate. One supplier is listed for this compound. Additional details are available on the plazomicin sulfate profile page.
Generic Entry Opportunity Date for 210303
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 210303
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||SOLUTION;INTRAVENOUS||Strength||EQ 500MG BASE/10ML (EQ 50MG BASE/ML)|
|Approval Date:||Jun 25, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jun 25, 2028|
|Regulatory Exclusivity Use:||GENERATING ANTIBIOTIC INCENTIVES NOW|
|Regulatory Exclusivity Expiration:||Jun 25, 2023|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Jun 2, 2031||Product Flag?||Substance Flag?||Y||Delist Request?|
|Patented Use:||METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS|
Complete Access Available with Subscription